Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Arqule Inc (NQ: ARQL)
7.880 USD  +0.050 (+0.64%)
Official Closing Price  /  Updated: 5:40 PM EST, Nov 15, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 3,152,100
Open 7.840
Bid (Size) 7.750 (3)
Ask (Size) 7.900 (1)
Prev. Close 7.830
Today's Range 7.650 - 7.950
52wk Range 2.230 - 12.22
Shares Outstanding 87,125,327
Dividend Yield N/A
Performance
YTD
+172.66%
+172.66%
1 Month
-15.36%
-15.36%
3 Month
-11.76%
-11.76%
6 Month
+16.74%
+16.74%
1 Year
+97.00%
+97.00%
Top News
More News
ArQule to Participate in the Jefferies London Healthcare Conference on November 20, 2019
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2019 in London, UK. Read More
from Business Wire News Releases
ArQule Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologi
ArQule, Inc. (Nasdaq: ARQL) today announced the publication of the abstract highlighting data, as of July 19, 2019, from the phase 1 trial of ARQ 531, the company’s potent and reversible dual inhibitor... Read More
from Business Wire News Releases
More News
Read More
ArQule Reports Third Quarter 2019 Financial Results
from Business Wire News Releases
ArQule Presents Recent Data on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
from Business Wire News Releases
Notable Tuesday Option Activity: JPM, MTSI, ARQL
category Stocks
from Market News Video
ArQule Announces Preclinical Data Demonstrating Potential of Miransertib (ARQ 092) to Treat PIK3CA-Driven Vascular Malformations at 2019 ASHG Annual Meeting
from Business Wire News Releases
ArQule Announces Presentations on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
from Business Wire News Releases
ArQule to Report Third Quarter 2019 Financial Results on October 30, 2019
from Business Wire News Releases
ArQule to Present Preclinical Data on Miransertib for the Treatment of Vascular Malformations at the 2019 American Society of Human Genetics (ASHG) Annual Meeting
from Business Wire News Releases
Notable Monday Option Activity: ARQL, PZZA, REAL
category Stocks
from Market News Video
ArQule Announces First Patient Dosed in Registrational MOSIAC Trial of Miransertib for the Treatment of Proteus Syndrome and PIK3CA-related Overgrowth Spectrum
from Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.